Fig. 2
From: Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model
BC-FAST and PCV treated mice control primary tumor growth. a Percentage of tumor free mice. Female Balb/c mice (n = 10/group) were challenged, vaccinated and tumor volume was measured twice per week. Mice were vaccinated with PBS (Mock), BC-PCV, BC-FAST, PC-FAST, or NR-PCV. Data are presented as percentage of tumor free mice and p values calculated using Log-rank (Mantel-Cox) Test. b Average 4 T1 tumor growth curves. The tumor volume of 4T1-tumor bearing mice was measured and plotted for BC-PCV, BC-FAST, or Mock vaccinated mice (b) and for PC-FAST and NR-PCV vaccinated mice (d). c Kaplan-Meyer survival curves of vaccinated mice. At 47–55 days post challenge, mice with tumor volume < 1000 mm3 and/or no clinical signs of illness (weight loss, skin ulceration, hair loss or lethargy) were considered survivors. Data were analyzed using Log-rank (Mantel-Cox) Test (*** p < 0.001)